Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

10.9K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.9K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

1.4K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
1.4K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

69.2K
Overview
69.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

577
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
577
Inflammatory Response01:28

Inflammatory Response

2.2K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Year in review 2012: Critical Care--Nephrology.

Critical care (London, England)·2013
Same author

Healthcare systems and chronic kidney disease: putting the patient in control.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2013
Same author

Neutrophil gelatinase associated lipocalin in acute kidney injury.

Postgraduate medicine·2013
Same author

Ultrafiltration therapy for acute decompensated heart failure: lessons learned from 2 major trials.

American heart journal·2013
Same author

Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference.

Kidney international·2013
Same author

Association between renal replacement therapy in critically ill patients with severe acute kidney injury and mortality.

Journal of critical care·2013
Same journal

Adsorption of Pathogens and Blockade of Sepsis Cascade.

Contributions to nephrology·2023
Same journal

Hemoadsorption: Research Agenda and Potential Future Applications.

Contributions to nephrology·2023
Same journal

Hemoperfusion in Poisoning and Drug Overdose.

Contributions to nephrology·2023
Same journal

Hemoperfusion in Burns.

Contributions to nephrology·2023
Same journal

Sequential Extracorporeal Therapy in Sepsis.

Contributions to nephrology·2023
Same journal

The Use of Adsorption in Extracorporeal Liver Support: The Double Plasma Molecular Adsorption System (DPMAS).

Contributions to nephrology·2023
See all related articles

Related Experiment Video

Updated: Jul 28, 2025

Use of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis
06:27

Use of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis

Published on: January 2, 2017

18.1K

Hemoperfusion and Immunomodulation.

Claudio Ronco1,2,3, Sara Samoni4, Rinaldo Bellomo5,6,7,8,9

  • 1Department of Medicine, University of Padova, Padova, Italy.

Contributions to Nephrology
|June 1, 2023
PubMed
Summary
This summary is machine-generated.

New sorbent technology enhances hemoperfusion (HP) potential for treating cytokine release syndromes and sepsis. This approach may safely remove harmful mediators in immune dysregulation, warranting further clinical studies.

More Related Videos

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.5K
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.3K

Related Experiment Videos

Last Updated: Jul 28, 2025

Use of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis
06:27

Use of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis

Published on: January 2, 2017

18.1K
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.5K
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.3K

Area of Science:

  • Biomedical Engineering
  • Clinical Medicine
  • Immunology

Background:

  • Sorbent technology advancements are renewing interest in hemoperfusion (HP).
  • Clinical applications are being explored for conditions like cytokine release syndromes and sepsis.
  • New sorbents offer improved biocompatibility and safety.

Purpose of the Study:

  • To evaluate the emerging potential of hemoperfusion in managing immune dysregulation.
  • To explore the use of advanced sorbents for enhanced hemoperfusion therapy.
  • To investigate the clinical plausibility of hemoperfusion for hyperinflammation and immunodepression.

Main Methods:

  • Review of recent developments in sorbent technology.
  • Analysis of small-scale studies on hemoperfusion efficacy.
  • Consideration of the peak concentration hypothesis for mediator removal.

Main Results:

  • New sorbents show promise for safer and more effective hemoperfusion.
  • Small studies suggest hemoperfusion is a plausible therapeutic approach.
  • The rationale for clinical application in immune-related disorders is strengthening.

Conclusions:

  • Hemoperfusion, utilizing advanced sorbents, presents a promising therapeutic avenue.
  • Further clinical studies are justified to solidify the role of HP in treating sepsis and CRS.
  • Targeted removal of mediator peaks may help manage hyperinflammatory and immunosuppressive states.